AbClon's (174900) gastric cancer treatment candidate 'ac101 (Henrius code name hlx22)' has begun phase 3 clinical trials in the United States, and the company's stock price is strong. AbClon ac101, combined with Enhertu, administered to the first patient in phase 2 clinical trials targeting breast cancer with low Her2 expression AbClon uses 'ac101' in combination with Enhertu to treat her2 low expression (low) and hormone receptor (hr) positive localization. Lee Yoon, head of the AbClon Clinical Research Institute, said, “Nespecel is showing groundbreaking results that present a new treatment option for seriously ill patients who have failed existing treatments,” and added, “More quickly through designation as an expedited treatment target.
WILLIAMS NELSON 09/14/2023 Kankakee County Mugshots Zone
Henriius received technology transfer for AbClone's ac101 twice in 2016 and 2018. Hlx22 originated from the antibody new drug candidate 'ac101' developed by 'Abclon', a domestic antibody drug development company. [Financial News] AbClone announced on the 28th that China's Henriius successfully held the '2025 Global Research and Development (r&d) Day' under the theme of 'collaborate to create.'
Looking at AbClon's foreign and institutional trading history over the past week, foreigners net purchased 37,060 shares, and institutions net purchased 16,665 shares.
[Prime Economy] AbClon (174900) received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ac101 (code name hlx22) for her2-positive locally advanced and metastatic gastric cancer.
